Publikasjonsdato: 30/06/2023 Selskap: Vifor Pharma Group Land: Norge Rapporteringsperiode: 01.01.2022-31.12.2022 Valuta: NOK HCPs: City of Inique country Principal Practice Principal Practice Country of Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a) Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c) Full Name identifier HCOs: City where Principal Practice Address OPTIONAL Donations and Grants registered to HCOs and Benefits Total in Kind to HCOs Optional Sponsorship agreements Related expenses agreed in the fee (Art. 3.01.1.a) with HCOs / third parties Travel & for service consultancy contract, (Art. 1.01) (Art. 3) (Schedule 1) (Art. 3) (Art. 3) **Registration Fees** Fees appointed by HCOs to Accommodation including travel & accommodation manage an Event relevant to the contract HCPs Parkveien 95, 8005-26 000,00 kr 2 000,00 kr 28 000,00 kr Hans-Arne Myhre BODØ BOD Norway OTHER, NOT INCLUDED ABOVE -Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02 60 086,00 kr 4 387,00 kr 64 473,00 kr Number of Recipients in aggregate disclosure - Art. 3.02 4 3 4 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients 66 67% 50.00% 66 67% HCOs Norsk Cardiologisk Ostadalsveien 12b, 136'000.00 kr 136'000.00 kr Selskap 0753-OSL Oslo Norway Abedini MD, PhD Halfdan Wilhelmsens 38000 38000 (org.nr 983939821) TØNSBERG Norway alle 17, 3103-TØN St Olavs Hospital Olav Kyrres gate 17, 11 500 00 kr 11 500.00 kr Trondheim TRONDHEIM 7030-TRO Norway DED A Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Number of Recipients in aggregate disclosure - Art. 3.02 0 0 0 0 0 0 0 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1 0 kr